These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25598933)

  • 41. Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
    Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Kim D; Kim HJ; Myung SC
    Gene; 2014 Jan; 533(1):86-93. PubMed ID: 24120391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
    Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
    Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
    Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
    Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.
    Makridakis NM; Ross RK; Pike MC; Crocitto LE; Kolonel LN; Pearce CL; Henderson BE; Reichardt JK
    Lancet; 1999 Sep; 354(9183):975-8. PubMed ID: 10501358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2.
    Wang Z; Hu L; Salari K; Bechis SK; Ge R; Wu S; Rassoulian C; Pham J; Wu CL; Tabatabaei S; Strand DW; Olumi AF
    J Pathol; 2017 Dec; 243(4):457-467. PubMed ID: 28940538
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
    Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
    Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic polymorphisms of 17 β-hydroxysteroid dehydrogenase 3 and the risk of hypospadias.
    Sata F; Kurahashi N; Ban S; Moriya K; Tanaka KD; Ishizuka M; Nakao H; Yahata Y; Imai H; Kakizaki H; Nonomura K; Kishi R
    J Sex Med; 2010 Aug; 7(8):2729-38. PubMed ID: 20059664
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genotyping the High Altitude Mestizo Ecuadorian Population Affected with Prostate Cancer.
    López-Cortés A; Cabrera-Andrade A; Salazar-Ruales C; Zambrano AK; Guerrero S; Guevara P; Leone PE; Paz-Y-Miño C
    Biomed Res Int; 2017; 2017():3507671. PubMed ID: 28685147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SRD5A2 gene polymorphisms affect the risk of breast cancer.
    Francis A; Sarkar S; Pooja S; Surekha D; Rao DR; Rao L; Ramachandra L; Vishnupriya S; Satyamoorthy K; Thangaraj K; Rajender S
    Breast; 2014 Apr; 23(2):137-41. PubMed ID: 24365257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
    Klein RJ; Hallden C; Gupta A; Savage CJ; Dahlin A; Bjartell A; Manjer J; Scardino PT; Ulmert D; Wallström P; Vickers AJ; Lilja H
    Eur Urol; 2012 Mar; 61(3):471-7. PubMed ID: 22101116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of polymorphisms in the SRD5A2 gene and semen parameters in Estonian men.
    Peters M; Saare M; Kaart T; Haller-Kikkatalo K; Lend AK; Punab M; Metspalu A; Salumets A
    J Androl; 2010; 31(4):372-8. PubMed ID: 19926884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of SRD5A2 genotype and pathological characteristics of prostate tumors.
    Jaffe JM; Malkowicz SB; Walker AH; MacBride S; Peschel R; Tomaszewski J; Van Arsdalen K; Wein AJ; Rebbeck TR
    Cancer Res; 2000 Mar; 60(6):1626-30. PubMed ID: 10749132
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population.
    Sobti RC; Onsory K; Al-Badran AI; Kaur P; Watanabe M; Krishan A; Mohan H
    DNA Cell Biol; 2006 May; 25(5):287-94. PubMed ID: 16716118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
    Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
    Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HNF1B polymorphism associated with development of prostate cancer in Korean patients.
    Kim HJ; Bae JS; Lee J; Chang IH; Kim KD; Shin HD; Han JH; Lee SY; Kim W; Myung SC
    Urology; 2011 Oct; 78(4):969.e1-6. PubMed ID: 21982019
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exome-based genome-wide association study and risk assessment using genetic risk score to prostate cancer in the Korean population.
    Oh JJ; Lee SJ; Hwang JY; Kim D; Lee SE; Hong SK; Ho JN; Yoon S; Sung J; Kim WJ; Byun SS
    Oncotarget; 2017 Jul; 8(27):43934-43943. PubMed ID: 28380453
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.
    Gustafsson O; Norming U; Gustafsson S; Eneroth P; Aström G; Nyman CR
    Br J Urol; 1996 Mar; 77(3):433-40. PubMed ID: 8814852
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population.
    Beikzadeh B; Angaji SA; Abolhasani M
    BMC Med Genet; 2020 Apr; 21(1):81. PubMed ID: 32295536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.